Please ensure Javascript is enabled for purposes of website accessibility

What You Need to Know About Allergan's Solid Q1 Performance

By Keith Speights – May 7, 2019 at 3:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Here's why the drugmaker topped revenue and earnings expectations in Q1.

Allergan (AGN) reported a deteriorating financial performance when it announced its fourth-quarter results in January. Revenue fell by nearly 6% year over year.

But any questions that investors had about Allergan's first quarter were answered when the drugmaker announced its Q1 results before the market opened on Tuesday. Here's what you need to know from the company's quarterly update:

Gloved hands holding a syringe and a vial of medicine

Image source: Getty Images.

By the numbers

Allergan reported revenue in the first quarter of $3.6 billion. This reflected a 2% decrease from the prior-year period total of $3.67 billion. The consensus among Wall Street analysts had Q1 revenue at $3.54 billion.

The company's GAAP net loss in the first quarter was $2.4 billion, or $7.25 per share. This was a worsening of Allergan's result in the prior-year period, when the company announced a net loss of $283.9 million, or $0.99 per share.

Allergan announced adjusted earnings of $3.79 per share in the first quarter. This represented a 1.34% increase from the $3.74 reported in the same quarter of 2018. Analysts were expecting Q1 adjusted EPS of $3.55.

Behind the numbers

One nice positive for Allergan in the first quarter was the performance of its flagship product Botox. Cosmetic sales for Botox increased 16.7% over the prior-year period to $229.5 million. Revenue from the therapeutic use of Botox jumped 5.8% year over year to $397.6 million. 

Allergan also saw good results from Juvederm. Sales for the gel dermal fillers increased 5.6% over the prior-year period to $129.7 million.

There was some bad news for Allergan in the first quarter, though. Sales for its CoolSculpting line slipped 27.8% to $62.9 million. And revenue generated by eye drop Restasis fell 9.4% to $231.7 million.

Looking ahead

Allergan now anticipates GAAP revenue between $15.13 billion and $15.43 billion in full-year 2019, up from its previous guidance of $15 billion to $15.3 billion. The company also projected 2019 non-GAAP revenue to be between $15.1 billion and $15.4 billion, compared with non-GAAP revenue between $15 billion and $15.3 billion provided in its previous outlook.

In addition, CEO Brent Saunders mentioned several things that investors can look forward to in the coming months. The company anticipates five regulatory approvals over the next 18 months. These new products could help maintain the momentum from the first quarter.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Allergan plc Stock Quote
Allergan plc

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.